Mammofield: mammofield

by William Olivadoti

non-contact, non-invasive, non-radiative experimental mammography research devices
Ticonderoga, NY United States Breast Cancer Cancer Diagnostics

All Team Company Patients Physicians Hospital Partners Mission Innovation Details Supporters Comments Updates

About our project

The problem we solve:
Early cancer cell detection

About our solution:
accidentally invented device; same recommended for cancer research by 2 University of California cancer researchers [one oncologist, one eye cancer specialist]; Two University cancer researchers recommended that mammofield® technology offers the possibility to be a reliable harbinger of cell-tumor screening as a complement to x-ray mammograms.; have one FDA regulatory expert, Have large pension fund and VC on board with matching co-investments. Recommended for melanoma clinical trials and also for early warning transplant organ failure by a NY medical college research oncologist.
Progress to date:

slow prototypes; fast units soon.


About Our Team

Creator: William Olivadoti
Location: New York
Education: none
Bio: accidental biometrics/medical device inventor- forty years in electronics management, (5 years in medical instrumentation and hospital electric/electronic systems, one year in nuclear medical mfg.), distribution, sales, govt & military sales, R&D, manufacturing experience; 8 years experience in government security
Hospital Affiliation: none
Title: CEO
Advanced Degree(s): - taught high-energy laser fusion construction methods to UC grad students at Lawrence Livermore LKaboratory

About Our Company

The William Olivadoti Company
Location: 53 Shore Airport Rd.
Box 212
Ticonderoga, New York 12883
Product Stage: Prototype/MVP
YTD Sales: Working on it
Employees: 1-2

How We Help Patients

Catch the cancer at cell level

How We Help Physicians

The mammofield technology can detect veryveryvery 
small bioelectric fields in a non-contact,
 non-invasive and non-radiative manner.

Cf. 
 Dr. Mchael Levin`s research on cell bioelectric field signatures 
 at Tufts wherein he speaks about in situ cancer cell bioelectric signatures; mammofield is extra-situ and is non-contact detection of cell biolectric field signatures  at a distance:

http://www.pddnet.com/news/2013/02/bioelectric-signals-
can-be-used-detect-early-cancer?et_cid=3070549&et_rid=45588976&linkid
=http%3a%2f%2fwww.pddnet.com%2fnews%2f2013%2f02%2fbioelectric-signals
-can-be-used-detect-early-cancer


How We Help Hospitals

complementary to mammograms
 


How We Help Partners

Complementary to mammograms


Challenge Mission

Key Milestones Achieved and Planned

PROJECTED INCOME STATEMENT
($ in Millions)
                         Year 1               Year 2      Year 3      Year 4       Year 5
                       ______            ______     ______     ______      ______
Revenues           9.3                    28.3          39.2         54.5          75.7
Cost of Revenue 2.7                      9.3          13.5         19.1          26.5
                          ------                   ------         ------          ------          ------

Gross Margin       6.6                     19.0        25.8        35.5            49.2



Our Competitive Advantages

William Olivadoti’s cancer research advisors concur that the mammofield® technology offers the possibility to be a reliable harbinger of cell-tumor screening as a complement to x-ray mammograms. The comparatively low-cost mammofield® detection system is non-contact, non-radiative, and non-invasive, being in a comfort zone for all patients. The mammary map produced by mammofield® will be both accurate and to cell level, allowing pinpoint accuracy, thus not allowing subjective conclusions to be drawn from observed data, a deficiency in x-ray mammography. Early cell tumor development detection is the asset of mammofield®, compared with x-ray screening’s sometimes tumor-decade-life before-detection period.
MARKETS: USA is a $3 billion mammography market. William Olivadoti’s mammofield® technology opens vast opportunities to facilitate initial-growth cell detection of breast tumors. mammofield® can increase the survival odds of women thru cell-level tumor identification. The market will welcome mammofield®’s new non-invasive, non-radiative and cell-level accurate tumor detection which will capture a large share of the preventive healthcare market. The targets will be researchers, clinics and hospitals. Trials may take place in other countries exchange for licensing rights to facilitate U.S. FDA acceptance.

Annual market

Hospitals                 $60 million &am

Barriers to Entry

COMPETITION:
TransScan has a non-invasive, non-radiation T-Scan product utilizing a multi-electrode sensor array pressed against the breast for detection of breast cancer based on TransSpectral Impedance Scanning . This is uncomfortable but has resulted in increased detection rates. There are currently four digital mammography manufacturers: General Electric, Fisher, LoRad, and Fuji. Standard x--ray mfg’s are: Advanced Instrument Development , Faxitron X-Ray Corporation, Fischer Imaging Corporation, GE Medical Systems, Instrumentarium Imaging, Inc., Philips Medical Systems and Toshiba America Medical Systems. Magnetic resonance imaging (MRI), ultrasound and thermal imaging are also being used. mammofield® provides for a greater cancer screening research methodology at lower cost, fewest parts, better reliability and more accurate capability than those or any other mammogram technology. A patent has been granted for this technology.



Traction, Funding and Partners

$0 bucks thus far; have a pension fund  @ $1.5 M and a VC ,  both ready to co-invest at end of clinical trails;

Innovation Details

Intellectual Property Summary

patented; also second patent to be pending

Clinical Information

medical device

Regulatory Status

have one FDA regulatory expert on board for clinicals

How we will use the funds raised

Funds to be spent for first research, clinical trials and commercial units/systems 

Thank You

Have pension fund committed and a VC  ready to match this  project funding or any fundings up to $1.5 million USD.  

Supporters

Comments

Login to post your comment!
Click here to Login

Updates

  • 4 oncologists now have recommended this project
    One oncologist from Univ. Of Cal. Med Ctr. & one cancer researcher from Univ. of Cal -Berkeley, have recommended this project for skin, tissue and beast cancer research; two oncologists from Albany Medical College have recommended the project for melanoma clinical trials. How many more cancer researchers do I need to get to recommend this project before it ever gets off the ground?

  • error
    should read "for skin, tissue and breast cancer research"

  • more
    M.D. Anderson Cancer Center: "All best on the development of your device...truly hope you make cancer history."

  • new bed
    The new Mammofield bed has 15 micron horizontal scan gaps combined with a 3 micron probe gives a hardware cut of 15/3 = 5 "looks" plus 50 looks at a cell scanning velocity = 5 x 50. = 250 "looks" [images] at a cell in one horizontal pass plus 27 horizontal scans/second = 27 x 250 = 6750 "looks" [images] per second at each cell. One micron probes give 3x magnification of the above cell image.

  • new [old] software
    New [old] software under development dumps scanned image of cell bioelectric field directly onto the computer screen as the cell is being scanned, thus allowing for immediate observation of the cell for anomalies etc.

  • slow bed
    The new bed is actually the slowest for experimentation because it is a single line scan. A future bed system would utilize multiple line scans in a parallel output.

  • IT
    engaged the services of an IT development firm to facilitate a database system to enable real-time cancer cell images/data-sharing via cloud technology for doctors, hospitals, clinics, and cancer research institutions, for the Mammofield cancer project.

  • second co-investor
    second co-investor to come on board @ $1,5 million USD; require lead investor

  • news
    Mammofield recommended for further cancer research by Cornell University and University of Buffalo.

$ 0

pledged of $ 10,000 goal

  • 36 Days left

66

Interest
Score

0

Adoption
Score


Rewards All contributions are tax-deductible.